secondary hyperparathyroidism (SHPT), bone abnormalities, and vascular calcification in patients with chronic kidney disease (CKD) are the components of chronic kidney disease-mineral bone disorder (CKD -MBD).1-3 This systemic disorder significantly contributes to the morbidity and mortality of patients with CKD. [4][5][6] SHPT (intact parathyroid hormone [iPTH] level >300 pg/ml) is diagnosed in 30% to 49% of dialyzed patients in Europe and even in 54% of those in the United States and Canada). 7 The diagnosis IntroductIon With progressive renal impairment and worsening of renal excretory function, the disorders of calcium and phosphorus metabolism become more severe. The increasing reduction of glomerular filtration results in lower phosphate excretion and, consequently, hyperphosphatemia. Phosphorus anions bond serum calcium cations, which leads to a reduction of ionized calcium levels. At the same time, a sustained high phosphate level inhibits vitamin D 3 synthesis.
AbstrActIntroductIon Secondary hyperparathyroidism (SHPT) is a common hormonal disorder associated with chronic kidney disease (CKD). The treatment of SHPT should lead to a reduction in parathormone concentrations by calcimimetics or active vitamin D administration and stabilization of calcium and phosphate metabolism. In the event of failure of conservative treatment, complete or partial parathyroid resection should be considered.